雷珠单抗(Ranibizumab (Genentech)) - 药物靶点：VEGF-A_在研适应症：糖尿病性视网膜病变，视网膜静脉阻塞，黄斑水肿_专利_临床

概要

基本信息

药物类型

Fab片段抗体

别名

ACCENTRIX、AMD Fab、AMD-rhuFab-V2

+ [19]

靶点

VEGF-A

作用方式

抑制剂

作用机制

VEGF-A抑制剂(血管内皮生长因子A抑制剂)

治疗领域

神经系统疾病心血管疾病遗传病与畸形+ [3]

在研适应症

糖尿病性视网膜病变视网膜静脉阻塞黄斑水肿+ [9]

非在研适应症

多灶性最佳玻璃体黄斑营养不良水疱缺血型视网膜中央静脉阻塞+ [33]

原研机构

Genentech, Inc.

在研机构

Novartis Europharm Ltd.Hoffmann-La Roche, Inc.

Genentech, Inc.

+ [8]

非在研机构

Novartis Pharmaceuticals Corp.

北京诺华制药有限公司Roche Registration GmbH

+ [4]

权益机构

Novartis AG

Genentech, Inc.

最高研发阶段批准上市

首次获批日期

美国 (2006-06-30),

湿性年龄相关性黄斑变性

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、孤儿药 (日本)、孤儿药 (澳大利亚)、优先审评 (中国)

登录后查看时间轴

结构/序列

Sequence Code 103170L

来源: *****

Sequence Code 143622H

来源: *****

关联

403

项与雷珠单抗相关的临床试验

NCT06847542

/ Not yet recruiting临床3期

A Phase IIIb, Multicenter, Single-arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration

The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.

开始日期2025-11-18

申办/合作机构

Hoffmann-La Roche Ltd.

[+1]

NCT07007065

/ Not yet recruiting临床3期

A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD).
Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis of previously treated nAMD will be enrolled. Around 561 participants will be enrolled in the study at approximately 150 sites worldwide.
Participants in groups 1 and 2 will receive a single subretinal dose of ABBV-RGX-314. Participants in group 3 will receive Ranibizumab as needed throughout the study. Ranibizumab will be given as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection), and ABBV-RGX-314 will be given as a subretinal (between the retina and the back of the eye) injection. The Assessment Period begins after randomization (1:1:1) to one of the ABBV-RGX-314 treatment groups or control at Week -2 and lasts up to 5 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2025-09-17

申办/合作机构

AbbVie, Inc.

ChiCTR2500095798

/ Suspended早期临床1期IIT

Clinical study of regulatory T cell exosomes combined with VEGF antibody (Ranibizumab) in the treatment of refractory exudative age-related macular degeneration

开始日期2025-01-16

申办/合作机构

河北省人民医院

100 项与雷珠单抗相关的临床结果

登录后查看更多信息

100 项与雷珠单抗相关的转化医学

登录后查看更多信息

100 项与雷珠单抗相关的专利（医药）

登录后查看更多信息

5,374

项与雷珠单抗相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan

Article

作者: Igarashi, Ataru ; Sakashita, Naotaka ; Shoji, Ayako ; Higashi, Kentaro ; Tsujimura, Jun ; Ohno, Shinya ; Yanagi, Yasuo

OBJECTIVE:

To assess the cost-effectiveness of faricimab vs. other anti-vascular endothelial growth factor (anti-VEGF) drugs for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in Japan, while considering societal burden associated with treatment.

METHODS:

A Markov model for cost-effectiveness analysis of anti-VEGF treatment in patients with nAMD and DME was applied based on cost and utility value data from Japan. Faricimab administered through a treat-and-extend (T&E) regimen was compared with ranibizumab administered pro re nata (PRN) and T&E, aflibercept T&E, brolucizumab T&E, and best supportive care (BSC). Further to treatment costs (public payer perspective), the societal burden (societal perspective), including costs of travel, informal care, and productivity, was assessed.

RESULTS:

In treatment of nAMD, lifetime quality-adjusted life years (QALYs) gained were highest with faricimab (faricimab T&E: 6.92, ranibizumab PRN: 6.88, ranibizumab T&E: 6.91, aflibercept T&E: 6.89, brolucizumab T&E: 6.89, BSC: 5.99). From the public payer perspective, the lifetime total cost for faricimab T&E was lower than those for ranibizumab (PRN, T&E) and brolucizumab (T&E), comparable to aflibercept T&E, and higher than BSC (incremental costs: 158,385 and 6,475,511 JPY, respectively). As a result, faricimab was cost-effective or dominant in the treatment of nAMD, excluding BSC. From the societal perspective, faricimab was dominant against all comparators in nAMD. In treatment of DME, QALYs gained were highest with faricimab (faricimab T&E: 8.51, ranibizumab PRN: 8.17, aflibercept PRN: 8.36, ranibizumab T&E: 8.13, BSC: 5.16). From both the public payer and societal perspectives, faricimab was dominant against all comparators in DME.

CONCLUSIONS:

When societal burdens were considered, faricimab was dominant in both nAMD and DME against all comparators, suggesting that the extended dosing interval associated with faricimab treatment may alleviate societal burdens and consequently improve patient outcomes.

2025-06-02·INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model

Article

作者: Ben-Arzi, Assaf ; Bahar, Irit ; Gal-Or, Orly ; Keshet, Yariv ; Spector, Itay ; Dotan, Assaf

Purpose:

Sustained increase in intraocular pressure (IOP) following intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in the treatment of retinal disease has been theoretically attributed to aggregation of anti-VEGF in the iridocorneal angle. However, previous studies by our group showed full clearance of intravitreally injected bevacizumab, aflibercept, and ranibizumab. The objective of this study was to further analyze and compare the clearance of these anti-VEGF agents from the eye after a single injection in a rat model.

Methods:

Brown Norway rats received an intravitreal injection of 3 µl anti-VEGF at the standard concentration 3 days following induction of choroidal neovascularization. The eyes were processed at 0, 3, 6, 24, and 48 hours thereafter, and immunofluorescence was evaluated with confocal microscopy and 3D reconstruction analysis. The signal concentration was calculated, and the drug clearance rate was measured. The immunohistochemistry process was validated with negative and positive control groups.

Results:

The immunofluorescent signal was positive for all anti-VEGF agents at the trabecular meshwork, Schlemm's canal, and episcleral veins. Anti-VEGF immunostaining peaked immediately after injection and then decreased gradually to negligible at 48 hours (P < 0.05). All three agents demonstrated an identical pattern (P > 0.05). The clearance rate of anti-VEGF from the iridocorneal angle ranged between 98.68% and 99.87% at 48 hours.

Conclusions:

Bevacizumab, aflibercept, and ranibizumab cleared completely from the iridocorneal angle at 48 hours in the brown Norway rats following a single intravitreal injection and with similar a clearance rate. These findings support our earlier studies refuting the anti-VEGF aggregation hypothesis.

2025-06-02·INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema

Article

作者: Aissa, Khadija ; Klaassen, Ingeborg ; Vader, Maartje J. C. ; Schlingemann, Reinier O. ; Tanck, Michael W. T.

Purpose:

This study aimed to identify genetic factors that may influence the effectiveness of anti-vascular endothelial growth factor (VEGF) treatment for macular edema (ME).

Methods:

We performed a genome-wide association study (GWAS) on 606 patients with macular edema that were treated with bevacizumab or ranibizumab from three randomized clinical trials, using a Infinium Global Screening Array. Well-characterized patient groups included diabetic macular edema (DME), retinal vein occlusion (RVO), and neovascular age-related macular degeneration (nAMD), with changes in best-corrected visual acuity (BCVA) and anatomical changes in central subfield thickness (CST) as outcomes. We conducted a meta-analysis on the combined patient groups, a targeted analysis on 28 previously reported genetic variants related to anti-VEGF response, and on variants of six genes involved in ME pathophysiology.

Results:

GWAS meta-analysis identified 12 SNPs (P < 1 × 10-6), of which three SNPs reached genome-wide significance (P < 5 × 10-8) and were linked to changes in CST after 6 months of anti-VEGF treatment. In addition, a genomic locus in the SGCZ gene was linked to changes in BCVA. Targeted GWAS revealed significant associations between changes in BCVA and variants in KDR, IL6, NRP1, and SPNS2, all known for their roles in VEGF signaling and retinal vascular permeability. Furthermore, changes in CST were associated with PLVAP, an important gene in vascular hyperpermeability in ME.

Conclusions:

This GWAS meta-analysis uncovered genetic variants potentially linked to responses to anti-VEGF treatment in patients with retinal conditions featuring vascular leakage and/or ME. These findings could aid in identifying genetic markers for treatment response prediction or uncover new pathways relevant to retinal vascular leakage and ME.

565

项与雷珠单抗相关的新闻（医药）

2025-06-04

·米内网

【瞩目】华东医药入局超16亿高端注射剂

精彩内容6月3日，华东医药发布公告，其全资子公司中美华东制药申报的3.3类新药雷珠单抗注射液上市申请获得受理。雷珠单抗注射液为重磅眼科生物药，2024年在中国三大终端六大市场销售额超过16亿元。今年以来，华东医药已有7款新品（按集团统计，下同）报产获受理，其中4款为生物制品。来源：公司公告雷珠单抗是罗氏和诺华合作研发的全球首个用于眼科的抗VEGF药物，可通过结合并阻断VEGF受体来减少血管内皮细胞增殖、血管渗漏和新血管生成，并促进已有的新生血管消退。罗氏负责美国市场的销售，诺华则负责美国之外的市场销售，2024年原研产品在全球的合计销售额超过12亿美元。2011年诺华的雷珠单抗获批进入中国，用于成人湿性（新生血管性）年龄相关性黄斑变性（AMD）、糖尿病性黄斑水肿（DME）引起的视力损害、糖尿病视网膜病变（DR）、继发于视网膜静脉阻塞（RVO）的黄斑水肿引起的视力损害等，以及早产儿视网膜病变（ROP）和AP-ROP（急进性后极部ROP）等多种眼科疾病。雷珠单抗注射液于2017年首次纳入医保后市场快速放量，2023-2024年在中国三大终端六大市场（统计范围详见本文末）的销售规模均超过16亿元，在眼科用药（化+生）产品格局中均高居TOP3，市场份额约8%。2024年中国三大终端六大市场眼科用药（化+生）产品TOP5来源：米内网格局数据库注：增长率不足5%用*表示米内网数据显示，除原研厂商诺华，目前已有齐鲁制药拥有雷珠单抗注射液的生产批文，华东医药提交上市申请在审，有望成为本品的国产第2家。截至目前，华东医药在雷珠单抗注射液项目的研发直接投入总金额近2.2亿元。今年以来华东医药报产在审新品情况来源：米内网中国申报进度（MED）数据库今年以来，华东医药已有7个新品报产获受理，包括4款生物药和3款化学药，其中司美格鲁肽注射液、乌司奴单抗注射液(静脉输注)、西甲硅油咀嚼片将冲击国产首家，磷酸芦可替尼片、雷珠单抗注射液有望冲击国产第2家。司美格鲁肽为降糖及减肥明星产品，乌司奴单抗是用于银屑病的“自免”新秀，芦可替尼为治疗骨髓纤维化的新型JAK1/JAK2抑制剂，其2024年在中国三大终端六大市场销售额分别超过60亿元、13亿元和8亿元。资料来源：米内网数据库、公司公告注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至6月4日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准申请上市

2025-06-03

·药圈头条

投入近2.2亿！华东医药「雷珠单抗」申报上市

6月2日，华东医药发布公告，其全资子公司杭州中美华东制药申报的的雷珠单抗注射液（研发代码：HJY28）上市许可申请获得受理。申报适应症：雷珠单抗是一种人源化的治疗性抗体片段，分子量为48KD，对VEGF-A各亚型（VEGF165、VEGF121、VEGF110等），尤其是VEGF165具有高亲和力。雷珠单抗通过结合VEGF-A，阻断VEGF-A与其受体VEGFR-1和VEGFR-2结合，抑制VEGF-A活性，从而抑制内皮细胞增殖、降低血管通透性，进而减少血管渗漏和新血管形成以及减少炎症反应，最终阻止AMD及RVO等疾病发生和发展。据公告披露，该产品原研参照药为Genentech开发的雷珠单抗注射液（中国市场上市许可持有人为NovartisPharmaSchweizAG），原研产品已分别于2006年6月获得美国FDA批准上市，2007年1月获得欧盟EMA批准上市，2009年3月获得日本医药品医疗器械综合机构（PMDA）批准上市，商品名为Lucentis®。2011年12月，原研在中国进口上市，商品名为诺适得®。雷珠单抗注射液自2017年起被纳入《国家基本医疗保险、工伤保险和生育保险药品目录》。华东医药于2024年11月完成一3项比较HJY28与诺适得®治疗中国湿性年龄相关性黄斑变性患者的有效性、安全性，以及药代动力学特征的多中心、随机、双盲、平行对照的临床试验，研究结果显示：在湿性年龄相关性黄斑变性患者中，华东医药雷珠单抗注射液与诺适得®疗效相当，包括目标眼首次给药后第16周和第52周BCVA较基线改善的字母数，以及第16周和52周对中心视网膜病损厚度、病损总面积及脉络膜新生血管病灶总面积的改善均相当。截至目前，华东医药在雷珠单抗注射液项目的研发直接投入总金额约为21,992万元。

上市批准

2025-06-03

·生物制品圈

国产第 2 款！华东医药「雷珠单抗」生物类似药申报上市

6 月 2 日，华东医药宣布，由中美华东申报的雷珠单抗注射液（研发代码：HJY28）上市申请已获得 NMPA 受理。Insight 数据库显示，这是国内第 2 款报上市的雷珠单抗生物类似药。截图来源：CDE 官网雷珠单抗是一种人源化的治疗性抗体片段，分子量为 48KD，对 VEGF-A 各亚型（VEGF165、VEGF121、VEGF110 等），尤其是 VEGF165 具有高亲和力。雷珠单抗通过结合 VEGF-A，阻断 VEGF-A 与其受体 VEGFR-1 和 VEGFR-2 结合，抑制 VEGF-A 活性，从而抑制内皮细胞增殖、降低血管通透性，进而减少血管渗漏和新血管形成以及减少炎症反应，最终阻止 AMD 及 RVO 等疾病发生和发展。雷珠单抗原研药已在美国、欧盟、日本、中国获批上市，中文商品名为诺适得，英文商品名为 Lucentis。根据诺华公司 2024 年财报，Lucentis 去年全年净销售额为 10.44 亿美元。HJY28 是华东医药自主立项开发，拥有全球权益。2021 年 4 月，HJY28 用于治疗湿性（新生血管性）年龄相关性黄斑变性适应症的临床试验申请获得批准。华东医药于 2024 年 11 月完成一项多中心、随机、双盲、平行对照的临床试验，该研究旨在比较 HJY28 与诺适得®治疗中国湿性年龄相关性黄斑变性患者的有效性、安全性，以及药代动力学特征。研究结果显示，在湿性年龄相关性黄斑变性患者中，HJY28 与诺适得®疗效相当，包括目标眼首次给药后第 16 周和第 52 周 BCVA 较基线改善的字母数，以及第 16 周和 52 周对中心视网膜病损厚度、病损总面积及脉络膜新生血管病灶总面积的改善均相当。根据 Insight 数据库，目前国内仅有诺华的原研诺适得和齐鲁的生物类似药 QL1205 获批上市。华东的 HJY28 是第 2 款报上市的雷珠单抗生物类似药。此外，杰科（天津）生物医药的类似药 JL14002 已进入 Ⅲ 期阶段。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

生物类似药财报临床3期上市批准

100 项与雷珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05697	雷珠单抗	S01LA04	DB01270

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病性视网膜病变	美国	Genentech, Inc.	2015-02-06
视网膜静脉阻塞	日本	Novartis Pharma AG	2013-08-20
黄斑水肿	美国	Genentech, Inc.	2010-06-22
年龄相关性黄斑变性	日本	Novartis Pharma AG	2009-01-21
伴有糖尿病的增殖性视网膜病变	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2008-11-10
早产儿视网膜病变	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2008-11-10
视力低下	澳大利亚	Novartis Pharmaceuticals Australia Pty Ltd.	2008-11-10
脉络膜新生血管	欧盟	Novartis Europharm Ltd.	2007-01-22
脉络膜新生血管	冰岛	Novartis Europharm Ltd.	2007-01-22
脉络膜新生血管	列支敦士登	Novartis Europharm Ltd.	2007-01-22
脉络膜新生血管	挪威	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	欧盟	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	冰岛	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	列支敦士登	Novartis Europharm Ltd.	2007-01-22
糖尿病性黄斑水肿	挪威	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞相关黄斑水肿	欧盟	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞相关黄斑水肿	冰岛	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞相关黄斑水肿	列支敦士登	Novartis Europharm Ltd.	2007-01-22
视网膜静脉阻塞相关黄斑水肿	挪威	Novartis Europharm Ltd.	2007-01-22
湿性年龄相关性黄斑变性	美国	Genentech, Inc.	2006-06-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
近视脉络膜新生血管	临床3期	中国	北京诺华制药有限公司	2013-09-11
近视脉络膜新生血管	临床3期	中国	Novartis Europharm Ltd.	2013-09-11
近视脉络膜新生血管	临床3期	中国	Novartis Pharma Stein AG	2013-09-11
近视脉络膜新生血管	临床3期	印度	Novartis Europharm Ltd.	2013-09-11
近视脉络膜新生血管	临床3期	印度	Novartis Pharma Stein AG	2013-09-11
近视脉络膜新生血管	临床3期	印度	北京诺华制药有限公司	2013-09-11
近视脉络膜新生血管	临床3期	韩国	Novartis Pharma Stein AG	2013-09-11
近视脉络膜新生血管	临床3期	韩国	Novartis Europharm Ltd.	2013-09-11
近视脉络膜新生血管	临床3期	韩国	北京诺华制药有限公司	2013-09-11
近视脉络膜新生血管	临床3期	泰国	北京诺华制药有限公司	2013-09-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


JPRN-jRCTs011200010 (HGCSG 1903, ASCO_GI2025)	临床2期	晚期胃癌二线	36	Ramucirumab plus Docetaxel	選襯蓋壓糧齋網艱衊廠(選鹽顧鹹鏇齋淵糧廠餘) = 膚鹹鹹觸鹽獵選淵窪範憲遞憲願選網築範鏇齋 (衊齋選齋鑰製遞繭糧窪 ) 更多	积极	2025-01-23
EURETINA2024	N/A	糖尿病性黄斑水肿	-	Aflibercept	鹹鹽齋鹽壓願窪鹹鏇積(窪壓網齋餘觸鏇蓋襯積) = 73% of eyes lacking DRIL demonstrated nearly three times higher odds of CMT reduction compared to eyes with DRIL present (OR 2.9) 獵衊積顧夢選獵廠襯觸 (膚窪醖窪範構鏇廠襯鹽 ) 更多	-	2024-09-19
				Ranibizumab
EURETINA2024	N/A	糖尿病性黄斑水肿	-	Ranibizumab (PDS Q24W)	顧膚選遞鹹蓋艱鬱夢鹹(淵簾淵膚廠膚選壓膚鏇) = 醖觸餘鬱顧鬱淵範鏇夢鹹製糧獵齋餘觸願衊齋 (簾廠窪範蓋餘觸糧蓋齋, 8.7 ~ 1.5) 更多	-	2024-09-19
				Monthly ranibizumab	顧膚選遞鹹蓋艱鬱夢鹹(淵簾淵膚廠膚選壓膚鏇) = 廠簾範艱鏇簾繭觸選夢鹹製糧獵齋餘觸願衊齋 (簾廠窪範蓋餘觸糧蓋齋, 8.3 ~ 10.5) 更多
EURETINA2024	N/A	糖尿病性视网膜病变	-	Port Delivery System with ranibizumab Q36W	襯鏇衊積鹹膚壓夢築壓(餘淵鑰製窪鑰壓蓋製窪) = No events of device dislocation were reported in either arm through W100 艱鏇膚鏇範淵窪夢觸顧 (醖憲積範窪淵膚蓋築廠 ) 更多	-	2024-09-19
				Ranibizumab (Control arm)
EURETINA2024	N/A	湿性年龄相关性黄斑变性	-	PDS with ranibizumab 100 mg/mL with fixed 24-week refill-exchanges (Q24W)	範鹽膚簾艱製襯淵鹽製(網願築憲糧鹽顧壓齋願) = 網鏇獵艱齋壓膚艱觸艱鏇齋願觸製窪衊衊繭窪 (醖鏇獵鬱遞艱壓窪鹽鏇 )	-	2024-09-19
				Intravitreal ranibizumab 0.5-mg injections every 4 weeks (monthly ranibizumab)	範鹽膚簾艱製襯淵鹽製(網願築憲糧鹽顧壓齋願) = 繭艱範憲選艱淵繭窪窪鏇齋願觸製窪衊衊繭窪 (醖鏇獵鬱遞艱壓窪鹽鏇 )
EURETINA2024	N/A	湿性年龄相关性黄斑变性	-	Intravitreal Ranibizumab (IVR)	選遞壓廠鹽範鏇遞鏇憲(鬱繭網艱願遞鏇艱繭願) = 鏇遞糧餘齋夢壓製繭網艱願鹽襯鹹窪膚壓餘餘 (夢糧製鹽廠夢鬱構夢構 ) 更多	-	2024-09-19
				Intravitreal Aflibercept (IVA)	選遞壓廠鹽範鏇遞鏇憲(鬱繭網艱願遞鏇艱繭願) = 鏇鏇觸選顧獵鬱繭襯範艱願鹽襯鹹窪膚壓餘餘 (夢糧製鹽廠夢鬱構夢構 ) 更多
EURETINA2024	N/A	玻璃体积血	-	Intravitreal Ranibizumab	積製願鏇膚積夢顧遞齋(窪鏇艱淵襯憲壓鏇願顧) = 獵衊遞醖醖窪齋鏇積壓願構觸鬱夢窪簾顧鏇窪 (憲製襯膚襯窪壓齋遞積 ) 更多	-	2024-09-19
EURETINA2024	N/A	早产儿视网膜病变	131	Intravitreal injection of Ranibizumab 0.25 mg/0.025 ml	積淵願窪壓鏇餘鑰餘構(蓋獵膚獵艱齋艱築蓋構) = 構顧築衊遞網觸築觸憲願糧鏇遞齋範夢壓窪範 (範鹽襯艱選齋窪憲選顧, 1.37) 更多	积极	2024-09-19
NCT02510794 \| NCT03683251 \| NCT03677934 (Archway \| Portal \| Ladder, EURETINA2024)	临床2/3期	湿性年龄相关性黄斑变性 vascular endothelial growth factor	-	Port Delivery System with ranibizumab (PDS)	醖鹹艱範壓鑰獵選構夢(範製鏇築襯築願壓蓋襯) = BCVA remained stable for 5 years, with an observed BCVA Snellen equivalent of 20/40 and mean (95% CI) change from baseline of −1.8 ETDRS letters (−8.1, 4.4; n=17) at month 60 壓簾鏇鹹夢遞簾襯築鹹 (願簾鏇鹹襯襯範積獵廠 ) 更多	积极	2024-09-19
				Monthly intravitreal ranibizumab injections
EURETINA2024	N/A	怀孕	-	Aflibercept	齋膚觸製範窪鏇範築淵(遞觸鏇鏇憲鑰範鏇壓艱) = 鹹網鑰簾蓋鏇觸製鑰構簾艱糧築繭製窪鏇選鑰 (獵簾獵簾觸鏇網窪繭鏇 )	-	2024-09-19
				Bevacizumab	齋膚觸製範窪鏇範築淵(遞觸鏇鏇憲鑰範鏇壓艱) = 觸範鹹壓廠構鏇糧網繭簾艱糧築繭製窪鏇選鑰 (獵簾獵簾觸鏇網窪繭鏇 )